The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

Exclusion Criteria

• •A patient will be withdrawn from the study if any of the following events occur while on therapy:
• •* Interruption of scheduled therapy for greater than 7 days
• •* Intolerable adverse effects which are judged by the investigator to be either physically or psychologically detrimental to the patient
• •* Patient decision to discontinue treatment
• •* Pregnancy
• •* Patient non-compliance with therapy administration
• •* Grade 3 or 4 NCI-CTC toxicity attributable to sorafenib
• •* Treatment with other chemotherapeutic or investigational anti-neoplastic drugs
• •* Disease progression
• •HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with sorafenib.Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated.